<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="182378">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00720226</url>
  </required_header>
  <id_info>
    <org_study_id>1P50HL084945</org_study_id>
    <secondary_id>1P50HL084945</secondary_id>
    <nct_id>NCT00720226</nct_id>
    <nct_alias>NCT00720044</nct_alias>
  </id_info>
  <brief_title>Efficacy of Losartan in Preventing Progression of COPD</brief_title>
  <official_title>Efficacy of Losartan in Preventing Progression of COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evidence in animals shows that losartan can prevent or reverse inflammation and lung damage
      due to smoking. The goal of this study is to determine whether this drug which is also used
      to treat hypertension can stabilize or improve lung function in people who have from chronic
      obstructive pulmonary disease (COPD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be given either losartan in a dose of 50-100 mg per day for a period of
      one year. During that time, they will have lung function tests, breathing tests, and
      computed tomograms of the chest. These tests will determine whether there is inflammation in
      the lung and whether there is progressive involvement of the lung with COPD.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Extent of emphysema on CT scan</measure>
    <time_frame>Measured at Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function testing</measure>
    <time_frame>Measured at Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>COPD</condition>
  <condition>Emphysema</condition>
  <condition>Chronic Bronchitis</condition>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan 100 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 pill daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Losartan 100 mg daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cozaar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill daily</description>
    <arm_group_label>2</arm_group_label>
    <other_name>&quot;Sugar pill&quot;</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with COPD who are either active or former smokers

        Exclusion Criteria:

          -  Clinical requirement or history of intolerance of angiotensin receptor blockers,
             serious heart, liver, kidney, neurological disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A. Wise, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Asthma and Allergy Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 1, 2013</lastchanged_date>
  <firstreceived_date>July 18, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Robert A. Wise</investigator_full_name>
    <investigator_title>Professor of Medicine (Pulmonary and Critical Care)</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>emphysema</keyword>
  <keyword>angiotensin receptor blocker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
